Hoboken, NJ — May 23, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease. After reviewing all the safety data from the first group of healthy human volunteers in the initial…
Hoboken, NJ — May 17, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and the Alzheimer’s Association, which have been updated for the first time in more than 25 years. The new guidelines discuss…
Hoboken, NJ — May 13, 2011 — Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced the appointment of Robert Chisholm to the Board of Directors. As a finance and administration executive with more than 25 years of experience, Mr. Chisholm brings to Anavex significant expertise in corporate finance, strategic business initiatives and the unique…
Expert Opin Ther Targets. 2011 May ; 15(5): 557–577. doi:10.1517/14728222.2011.560837. Hayashi Teruo*, Tsai Shang-Yi, Mori Tomohisa, Fujimoto Michiko, and Su Tsung-Ping View Poster
